Buy & Sell Synchrony Financial (SYF) – Synchrony Financial Price Today
Aura AI Summary
Key Stats
- $23.90BMarket Cap
- FinancialsSector
- -13.79%3M Drawdown
- -Enterprise Value
- 1.69%Dividend Yield
- 29 daysTypical Hold Time
Synchrony Financial (SYF) is currently valued at a market capitalization of $23.90B. Over the past 52 weeks, Synchrony Financial has traded between a low of $56.74 and a high of $88.47, highlighting its annual price range. Over the past three months, Synchrony Financial has recorded a drawdown of -13.79%, reflecting recent price volatility. Synchrony Financial offers a dividend yield of 1.69%, with the most recent dividend of $0.30 paid on 05 May 26. On average, investors hold Synchrony Financial for approximately 29 days, indicating typical investor behavior on the platform.
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Most Recent News
Short seller warns Everspin stock is overvalued amid AI hype, predicts 60% downside.
Kerrisdale Capital has taken a short position on Everspin Technologies, arguing the recent surge in its stock price is driven by misplaced enthusiasm around AI-related memory demand. Everspin's MRAM technology targets niche industrial markets rather ...

Vuzix showcases advanced waveguide smart glasses for defense at SOF Week 2026 in Florida
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...

Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
